Evidence map›Paper›PMID 40926130›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Prognostic value of [

Michael Müther, Lorenz König, Philipp Backhaus, Walter Stummer, Oliver M Grauer, Michael Schäfers, Philipp Schindler, Matthias Weckesser, Wolfgang Roll

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Journal of neuro-oncology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michael MütherDepartment of Neurosurgery, University Hospital Münster, Münster, Germany.
Lorenz KönigDepartment of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Philipp BackhausDepartment of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Walter StummerDepartment of Neurosurgery, University Hospital Münster, Münster, Germany.
Oliver M GrauerWest German Cancer Center, Münster, Germany.
Michael SchäfersDepartment of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Philipp SchindlerWest German Cancer Center, Münster, Germany.
Matthias WeckesserDepartment of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Wolfgang RollDepartment of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany. wolfgang.roll@ukmuenster.de.ORCID 0000-0002-3746-9393

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAmino acid PET with [

methodsRetrospectively, all therapy-naive patients having undergone [

resultsIn the cohort of WHO grade 2 gliomas, 57 (69%) patients were diagnosed with astrocytoma, IDH-mutant. Twenty-six (31%) patients were diagnosed with oligodendroglioma, IDH-mutant and 1p/19q-codeleted. Quantitative PET uptake parameters (TBR

conclusionPreoperative [

Indexed as

Brain NeoplasmsGliomaPositron-Emission TomographyTyrosineAdultAgedFemaleHumansMaleMiddle AgedNeoplasm GradingPrognosisRetrospective Studies(18F)fluoroethyltyrosineTyrosine18F-FETAmino acid PETLow-grade glioma

Identifiers

PMID40926130
PMCPMC12860753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.